• About
• Links
• Contact
• Sitemap
• 

Huntington's Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Summary
Huntington’s disease – Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global huntington’s disease market. This pharma report identifies the key trends shaping and driving the global huntington’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global huntington’s disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by industry experts.

Scope

The scope of the report includes:

Annualized global huntington’s disease revenues data from 2001 to 2009, forecast forward for 7 years to 2016.

Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.

Analysis of the current and future market competition in the global huntington’s disease market. Key companies covered include Amarin Corporation, Medivation Inc. and NeuroSearch

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with huntington’s disease.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global huntington’s disease market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global huntington’s disease market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global huntington’s disease market landscape? – Identify, understand and capitalize.

Table of Contents

 

 

1 Table of contents 3

• 1.1 List of Tables 5
• 1.2 List of Figures 5

2 Huntington’s Disease: Market Characterization 6

• 2.1 Overview 6
• 2.2 Huntington’s Disease Market Size 6
• 2.3 Huntington’s Disease Market Forecast and CAGR 7
• 2.4 Drivers and Barriers for the Huntington’s Disease Market 8
  • 2.4.1 Drivers for the Huntington’s Disease market 8
  • 2.4.2 Barriers for the Huntington’s Disease market 9
• 2.5 Opportunity and Unmet Need 9
• 2.6 Key Takeaway 10

3 Huntington’s Disease Market: Competitive Assessment 12

• 3.1 Overview 12
• 3.2 Strategic Competitor Assessment 12
• 3.3 Product Profile for the Major Marketed Products in the Huntington’s Disease 13
  • 3.3.1 XENAZINE (tetrabenazine) 13
• 3.4 Key Takeaway 14

4 Huntington’s Disease: Pipeline Assessment 15

• 4.1 Overview 15
• 4.2 Strategic Pipeline Assessment 15
  • 4.2.1 Technology Trends Analytic Framework 15
• 4.3 Huntington’s Disease Therapeutics – Promising Drugs under Clinical Development 16
• 4.4 Molecule Profile for Promising Drugs under Clinical Development 18
  • 4.4.1 AMR-101 (Miraxion) (Amarin Pharmaceuticals) 18
  • 4.4.2 Dimebon (latrepirdine) (Medivation/Pfizer) 19
  • 4.4.3 Huntexil (ACR16) (NeuroSearch) 20
  • 4.4.4 Coenzyme Q10 (CoQ) (National Institute of Neurological Disorders and Stroke - NINDS) 21
• 4.5 Huntington’s Disease Therapeutics– Clinical Pipeline by Mechanism of Action 22
  • 4.5.1 Huntington’s Disease Pipeline – Pipeline by Clinical Phases of Development 23
  • 4.5.2 Huntington’s Disease Therapeutics – Phase III Clinical Pipeline 23
  • 4.5.3 Huntington’s Disease Therapeutics – Phase II Clinical Pipeline 23
  • 4.5.4 Huntington’s Disease Therapeutics – Phase I Clinical Pipeline 24
  • 4.5.5 Huntington’s Disease Therapeutics – Preclinical Phase Pipeline 24
  • 4.5.6 Huntington’s Disease Therapeutics – Discovery Pipeline 24
• 4.6 Key Takeaway 24

5 Huntington’s Disease Market: Implications for Future Market Competition 25

6 Huntington’s Disease Market: Future Players in the Huntington’s Disease Market 27

• 6.1 Introduction 27
• 6.2 Amarin Corporation, Ireland 28
  • 6.2.1 Overview 28
  • 6.2.2 CNS Portfolio 28
  • 6.2.3 Huntington’s Disease Portfolio 28
• 6.3 Medivation Inc., the US 29
  • 6.3.1 Overview 29
  • 6.3.2 CNS Portfolio 30
  • 6.3.3 Huntington’s Disease Portfolio 30
• 6.4 NeuroSearch, Denmark 31
  • 6.4.1 Overview 31
  • 6.4.2 CNS Portfolio 32
  • 6.4.3 Huntington’s Disease Portfolio 32
• 6.5 National Institute of Neurological Disorders and Stroke, the US 34
  • 6.5.1 Overview 34
  • 6.5.2 Huntington’s Disease Portfolio 34

7 Huntington’s Disease Market: Appendix 36

• 7.1 Market Definitions 36
• 7.2 Abbreviations 36
• 7.3 Research Methodology 37
  • 7.3.1 Coverage 37
  • 7.3.2 Secondary Research 38
  • 7.3.3 Forecasting 38
  • 7.3.4 Primary Research 40
  • 7.3.5 Expert Panel Validation 41
• 7.4 Contact Us 41
• 7.5 Disclaimer 41
• 7.6 Sources 41

"

1.1 List of Tables

• Table 1: Huntington’s Disease, Global, Market Revenues ($m), 2001-09 7
• Table 2: Huntington’s Disease, Global, Market Forecast ($m), 2009-2016 8
• Table 3: Major Marketed Product in the Huntington’s Disease Market, 2010 14
• Table 4: Huntington’s Disease Therapeutics – Most Promising Drugs Under Clinical Development, 2010 16
• Table 5: Huntington’s Disease Therapeutics – Phase III Clinical Pipeline, 2010 23
• Table 6: Huntington’s Disease Therapeutics – Phase II Clinical Pipeline, 2010 23
• Table 7: Huntington’s Disease Therapeutics – Phase I Clinical Pipeline, 2010 24
• Table 8: Huntington’s Disease Therapeutics – Preclinical Phase Pipeline, 2010 24
• Table 9: Huntington’s Disease Therapeutics – Discovery Pipeline, 2010 24
• Table 10: Amarin – CNS Pipeline Products, 2010 28
• Table 11: Amarin – Huntington’s Disease Pipeline Products, 2010 28
• Table 12: Medivation – CNS Pipeline Products, 2010 30
• Table 13: Medivation – Huntington’s Disease Pipeline Products, 2010 30
• Table 14: NeuroSearch – CNS Pipeline Products, 2010 32
• Table 15: NeuroSearch – Huntington’s Disease Pipeline Products, 2010 32
• Table 16: NINDS – Huntington’s Disease Pipeline Products, 2010 34

"

1.2 List of Figures

• Figure 1: Huntington’s Disease, Global, Market Revenues ($m), 2001-2009 7
• Figure 2: Huntington’s Disease, Global, Market Forecast ($m), 2009-2016 8
• Figure 3: Opportunity and Unmet Need in the Huntington’s Disease Market, 2010 10
• Figure 4: Strategic Competitor Assessment of the Marketed Products for Huntington’s Disease, 2010 12
• Figure 5: Technology Trends Analytic Framework of the Huntington’s Disease Pipeline – 2010 15
• Figure 6: Technology Trends Analytic Framework of the Huntington’s Disease Pipeline – Description, 2010 16
• Figure 7: Huntington’s Disease Therapeutics– Clinical Pipeline by Mechanism of Action, 2010 22
• Figure 8: Huntington’s Disease Pipeline by Phase of Clinical Development, 2010 23
• Figure 9: Implications for Future Market Competition in the Huntington’s Disease Market, 2010 25
• Figure 10: Huntington’s Disease Market – Clinical Pipeline by Company, 2010 27
• Figure 11: Methodology 37
• Figure 12: Market Forecasting Model 40

Other users found this report page using the following search terms: Huntington's Disease disease huntingtons market huntington pipeline drug drugs huntingtonsdiseasepipeline huntingtondiseasepipeline size

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.